The University of Arizona Cancer Center has received an $8.6 million grant from the National Cancer Institute for the UA Cancer Prevention Clinical Trials Network, one of only three such networks funded by the NCI.Continue reading
Centers for Medicare and Medicaid Services Makes It Easier for Healthcare Providers to Choose Axolotl Biologix Products to Spur Wound and Tissue RegenerationContinue reading
TUCSON, Arizona, October 23, 2019 – The CATS Tonometer Reusable Prism™ is now available for order through a variety of key distributors in the United States. A breakthrough in intraocular pressure (IOP) accuracy, the CATS Tonometer Prism™ establishes a new standard in reliable Goldmann IOP measurement.Continue reading
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both discovery research and pre-clinical development to evolve SO’s rapidly expanding pipeline of innovative cancer therapeutics.
Developed by a research team at the University of Arizona College of Medicine – Phoenix, the self-collection device quickly can evaluate radiation exposure and help triage emergency treatment in the event of a nuclear attack or accident.Continue reading
TUCSON, Ariz. and AUSTIN, Texas, October 15, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule. The Animal Rule provides a regulatory mechanism for the approval of drugs and licensure of biological products when human efficacy studies are not ethical or feasible.Continue reading
TUCSON, Ariz., Oct. 15, 2019 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory at the end of October 2019. The HTG EdgeSeq Autoimmune Panel provides a comprehensive look into immune system dysfunction, discovery of new biomarkers and the discovery of predictive signatures of drug response in the autoimmune space. The panel is designed to address many questions around autoimmune disorders, which are chronic and often difficult to accurately diagnose. Autoimmune disorders represent a large and growing market, with annual direct U.S. healthcare costs for the treatment of autoimmune disorders being nearly double the direct U.S. healthcare costs for the treatment of cancer, and several of the largest selling pharmaceutical products are targeted towards autoimmune diseases.Continue reading